staurosporine has been researched along with cytarabine in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 13 (27.66) | 29.6817 |
| 2010's | 13 (27.66) | 24.3611 |
| 2020's | 11 (23.40) | 2.80 |
| Authors | Studies |
|---|---|
| Akaho, E; Ali, HI; Ashida, N; Hayakawa, H; Ikeya, H; Kambara, H; Kawashima, Y; Miura, S; Nagamatsu, T; Tomita, K; Yamagishi, T; Yoneda, F | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Kato, Y; Ogawa, K; Okuda, T; Sawada, H; Tashima, M; Ueda, T; Yumoto, Y | 1 |
| Chorvath, B; Duraj, J; Hunakova, L; Novotny, L; Sedlak, J | 1 |
| Bartimole, TM; Grant, S; Jarvis, WD; Joe, VC; Nelms, PA; Turner, AJ | 1 |
| Bouffard, DY; Momparler, RL | 1 |
| Chorváth, B; Duraj, J; Hunáková, L; Sedlák, J; Suliková, M | 1 |
| Holian, O; Roninson, IB; Shtil, AA; Walter, RJ | 1 |
| Fang, M; Wang, RH; Xue, SB; Zhang, HQ | 1 |
| Bartimole, TM; Dent, P; Freemerman, AJ; Grant, S; Jarvis, WD; Kramer, LB; Krystal, G; Vrana, JA; Wang, S | 1 |
| Carr, BK; Deng, X; May, WS; Ruvolo, PP | 1 |
| Bigas, A; Chernukhin, IV; Delgado, MD; Klenova, EM; León, J | 1 |
| D'Sa-Eipper, C; Roth, KA | 1 |
| Bharti, A; Farber, R; Kharbanda, S; Kufe, D; Kumar, S; Nakazawa, A; Nalin, C; Pandey, P; Weichselbaum, R | 1 |
| Boise, LH; Dent, P; Grant, S; Tang, L | 1 |
| Bieszczad, CK; Cleaveland, ES; Craig, RW; Ma, Y; Mohandas, TK; Park, JP; Vrana, JA | 1 |
| Grant, S; Wang, S; Wang, Z | 1 |
| Bagrintseva, K; Eichenlaub, S; Ellwart, JW; Hiddemann, W; Kohl, TM; Schnittger, S; Schwab, R; Spiekermann, K | 1 |
| Cao, CX; Pommier, Y; Shao, RG | 1 |
| Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
| Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kirito, K; Mano, H; Matsuo, Y; Odgerel, T; Sato, Y; Tsunoda, S; Vu, HA | 1 |
| Tallman, M | 1 |
| Karp, J | 1 |
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Camós, M; Català, A; Caviedes-Cárdenas, L; Fernández-Calotti, P; Malatesta, R; Pastor-Anglada, M; Rives, S; Vega-García, N | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; de Witte, T; Döhner, H; Döhner, K; Ehninger, G; Ganser, A; Geyer, S; Klisovic, RB; Krauter, J; Larson, RA; Laumann, K; Lo-Coco, F; Mandrekar, SJ; Marcucci, G; Medeiros, BC; Niederwieser, D; Prior, TW; Sanford, BL; Sanz, MA; Schlenk, RF; Serve, H; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Wei, A | 1 |
| Tiong, IS; Wei, AH | 2 |
| Kim, M; Williams, S | 1 |
| Cortes, JE; Rytting, ME; Short, NJ | 1 |
| Sweet, K; Talati, C | 1 |
| Bhattacharyya, S; Bonifacio, G; Duchesneau, E; Guerin, A; Joseph, G; Li, N; Ndife, B; Stein, E; Vudumula, U; Xie, J | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Ojha, S; Ooi, MG | 1 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Estey, EH | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Cerchione, C; Martinelli, G | 1 |
| Beatty, CJ; Ghareeb, ER | 1 |
| Schuh, AC; Tang, K; Yee, KW | 1 |
| Cenin, DA; Donald Harvey Iii, R; Kovacsovics, T; Kurish, HP; Lee, JS; Li, BKT; Lo, M; Patel, S; Prelewicz, S; Schlafer, D; Wagner, CB; Walchack, R; Wasef, B; Ying, J | 1 |
11 review(s) available for staurosporine and cytarabine
| Article | Year |
|---|---|
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
Acute myeloid leukaemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Gemtuzumab; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Patient Selection; Recurrence; Remission Induction; Risk Assessment; Risk Factors; Staurosporine | 2018 |
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines | 2018 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Sulfonamides; United States | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Risk Assessment; Staurosporine | 2021 |
4 trial(s) available for staurosporine and cytarabine
| Article | Year |
|---|---|
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Cycle; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cytarabine; DNA Damage; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Protein v-akt; Pharmacokinetics; Phosphorylation; Pilot Projects; Protein Kinases; Salvage Therapy; Staurosporine; Tumor Cells, Cultured | 2006 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2017 |
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Theoretical; Quality-Adjusted Life Years; Staurosporine; Survival Rate; Treatment Outcome; United States | 2019 |
32 other study(ies) available for staurosporine and cytarabine
| Article | Year |
|---|---|
Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Drug Design; Drug Screening Assays, Antitumor; Flavins; Humans; Ligands; Models, Molecular; Molecular Structure; Oxides; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2007 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of second-messenger modulators in K-562 cell differentiation: dual action of calcium/phospholipid-dependent protein kinase in the process of differentiation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Blotting, Northern; Bucladesine; Cell Differentiation; Cell Division; Cell Survival; Cytarabine; Diglycerides; Erythropoiesis; Globins; Hemin; Humans; In Vitro Techniques; Isoquinolines; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; RNA, Messenger; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1990 |
Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines.
Topics: Alkaloids; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Cycle; Cytarabine; DNA Replication; DNA, Neoplasm; Drug Resistance, Multiple; Drug Synergism; Female; Humans; Leukemia L1210; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred DBA; Neoplasm Proteins; Ovarian Neoplasms; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
Topics: Alkaloids; Apoptosis; Arabinofuranosylcytosine Triphosphate; Cytarabine; DNA Damage; Drug Synergism; Gene Expression; Genes, jun; Humans; Leukemia, Promyelocytic, Acute; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1994 |
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Northern; Cytarabine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Gene Expression; Genes, fos; Genes, jun; HL-60 Cells; Humans; Leukemia, T-Cell; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (AraC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; DNA, Neoplasm; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Genistein; HL-60 Cells; Humans; Isoflavones; Protein Kinase C; Staurosporine | 1996 |
60-Hz electric fields inhibit protein kinase C activity and multidrug resistance gene (MDR1) up-regulation.
Topics: Cytarabine; Cytosol; Drug Resistance, Multiple; Electricity; Enzyme Inhibitors; Gene Expression Regulation; Genes, MDR; Humans; Leukemia, T-Cell; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1997 |
[Protein kinase inhibitor staurosporine enhances cytotoxicity of antitumor drugs to cancer cells].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bleomycin; Cells, Cultured; Cytarabine; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Fibroblasts; Humans; Staurosporine; Stomach Neoplasms; Tumor Cells, Cultured | 1996 |
Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Bryostatins; Cytarabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Endopeptidases; Enzyme Inhibitors; HL-60 Cells; Humans; Lactones; Macrolides; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine | 1997 |
A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cytarabine; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Mitochondria; Phosphorylation; Protein Kinase C; Protein Kinase C-alpha; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Transfection | 1998 |
Differential expression and phosphorylation of CTCF, a c-myc transcriptional regulator, during differentiation of human myeloid cells.
Topics: Blotting, Northern; Blotting, Western; Burkitt Lymphoma; CCCTC-Binding Factor; Cell Differentiation; Cytarabine; Dimethyl Sulfoxide; DNA-Binding Proteins; Down-Regulation; Erythrocytes; Gene Expression Regulation; Humans; Isoelectric Focusing; Leukemia, Myeloid; Leukocytes; Megakaryocytes; Phosphorylation; Proto-Oncogene Proteins c-myc; Repressor Proteins; RNA Processing, Post-Transcriptional; Staurosporine; Tetradecanoylphorbol Acetate; Transcription Factors; Tretinoin; Tumor Cells, Cultured | 1999 |
Caspase regulation of neuronal progenitor cell apoptosis.
Topics: Animals; Apoptosis; Caspase Inhibitors; Caspases; Cytarabine; Embryo, Mammalian; Enzyme Activation; Enzyme Inhibitors; Mice; Neurons; Staurosporine; Stem Cells; Telencephalon | 2000 |
Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3.
Topics: Actins; Apoptotic Protease-Activating Factor 1; Caspase 3; Caspase 9; Caspases; Cell Line; Cell-Free System; Cytarabine; Cytochrome c Group; Cytosol; Enzyme Activation; Enzyme Inhibitors; Enzyme Precursors; Heat-Shock Proteins; Humans; Immunoblotting; Isoenzymes; Methyl Methanesulfonate; Oligopeptides; Protein Kinase C; Protein Kinase C-delta; Proteins; Staurosporine | 2000 |
Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cytarabine; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia; Mitochondria; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells | 2000 |
An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Burkitt Lymphoma; Camptothecin; Cell Survival; Culture Media, Serum-Free; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2002 |
Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bryostatins; Carrier Proteins; Caspases; Cytarabine; Cytochrome c Group; Drug Synergism; Enzyme Activation; Gene Deletion; HL-60 Cells; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Lactones; Leukemia, Myeloid; Macrolides; Maleimides; Mitochondrial Proteins; Mutation; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Staurosporine; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; U937 Cells | 2003 |
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Transformed; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Genistein; Humans; Indoles; Leukemia, Myeloid; MAP Kinase Signaling System; Milk Proteins; Mutagenesis; Phenotype; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; STAT5 Transcription Factor; Staurosporine; Trans-Activators; Tyrphostins | 2004 |
Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells.
Topics: Antineoplastic Agents; CDC2-CDC28 Kinases; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Cyclin A; Cyclin B; Cyclin-Dependent Kinase 2; Cytarabine; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; HT29 Cells; Humans; Protein Kinases; S Phase; Staurosporine | 2004 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytarabine; Doxorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia; Methotrexate; Mitoxantrone; Mutation; Protein Kinase C; Staurosporine | 2007 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
Topics: Adolescent; Apoptosis; Biological Transport; Cell Line, Tumor; Child; Child, Preschool; Cytarabine; DNA Mutational Analysis; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Histone-Lysine N-Methyltransferase; Humans; Infant; Infant, Newborn; Male; Mutation; Myeloid-Lymphoid Leukemia Protein; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine | 2016 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Pregnancy exposure to midostaurin in the first trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Compassionate Use Trials; Cytarabine; Female; Fetal Growth Retardation; fms-Like Tyrosine Kinase 3; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Protein Kinase Inhibitors; Recurrence; Staurosporine; Tandem Repeat Sequences | 2020 |
Acute leukemias in 2020: state of the art.
Topics: Acute Disease; Aminopyridines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Congresses as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia; Pyridines; Recombinant Fusion Proteins; Staurosporine; Triazines | 2020 |
Neutrophilic Eccrine Hidradenitis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hidradenitis; Humans; Leukemia, Monocytic, Acute; Staurosporine | 2021 |
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Staurosporine | 2023 |